HC Wainwright set a $4.00 price objective on Pluristem Therapeutics (NASDAQ:PSTI) in a research report report published on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Separately, B. Riley assumed coverage on shares of Pluristem Therapeutics in a report on Tuesday, July 31st. They set a buy rating and a $4.50 target price on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $3.25.

NASDAQ:PSTI opened at $1.10 on Monday. The firm has a market cap of $135.49 million, a P/E ratio of -4.40 and a beta of 0.48. Pluristem Therapeutics has a twelve month low of $1.05 and a twelve month high of $1.65.

Pluristem Therapeutics (NASDAQ:PSTI) last posted its earnings results on Thursday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. Research analysts forecast that Pluristem Therapeutics will post -0.37 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of PSTI. ARK Investment Management LLC lifted its holdings in Pluristem Therapeutics by 101.3% in the 3rd quarter. ARK Investment Management LLC now owns 2,892,231 shares of the biotechnology company’s stock worth $3,760,000 after buying an additional 1,455,730 shares in the last quarter. Virtu Financial LLC lifted its holdings in Pluristem Therapeutics by 964.8% in the 3rd quarter. Virtu Financial LLC now owns 174,174 shares of the biotechnology company’s stock worth $523,000 after buying an additional 157,816 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Pluristem Therapeutics by 5.8% in the 3rd quarter. Renaissance Technologies LLC now owns 1,331,100 shares of the biotechnology company’s stock worth $1,730,000 after buying an additional 72,600 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in Pluristem Therapeutics by 337.4% in the 3rd quarter. Jane Street Group LLC now owns 94,023 shares of the biotechnology company’s stock worth $122,000 after buying an additional 72,526 shares in the last quarter. Hedge funds and other institutional investors own 3.56% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

See Also: What are no-load funds?

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.